Clinical Trial Update: Iressa/Docetaxel in Non-Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of Iressa (gefitinib) with docetaxel for non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)
• Taxotere (docetaxel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN